In recent developments, the ENVISION phase 3 clinical trial evaluating givosiran, an RNA inhibitor targeting ALAS protein translation, exhibited promising results, demonstrating a notable 74% decrease in the annual occurrence of AIP attacks within a cohort of 94 patients [19]. Here, ALAS1 is linked to autoimmune pancreatitis.